BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $16.56 Consensus PT from Brokerages
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the nine brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month target price […]
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the nine brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month target price […]
